Roth Capital Resumes Flex Pharma (FLKS) at Buy

January 3, 2018 7:39 AM EST Send to a Friend
Roth Capital resumes coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $12.00.Analyst Jotin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login